First Immunotherapy Treatment Approved for Stage III
February 16, 2018
Friday, February 16, 2018. Today the Food and Drug Administration (FDA) approved Imfinzi (durvalumab), the first immunotherapy drug for stage III non-small cell lung cancer. This approval is what is called "maintenance" therapy, which is when you take a drug to help prevent cancer from growing or coming back following earlier treatment protocols. Learn more now.
Lung cancer questions? Contact our free HelpLine at support@go2.org or 1-800-298-2436.